MOLECULAR DOCKING OF VARIOUS ALKALOIDS AGAINST ABL-KINASE FOR ANTI-CHRONIC MYELOID LEUKEMIC PROPERTY

Abstract

Chronic myeloid leukemia is a bone marrow cancer that results from the reciprocal translocation of chromosomes 9 and 22, which produces the activated tyrosine kinase that results in unchecked cell proliferation and various other signaling cascades that block apoptosis. Tyrosine kinase inhibitors, like nilotinib, effectively slow the course of CML but not in drug resistance. Despite the availability of a variety of Tyrosine Kinase Inhibitors (TKI), treatments are rendered ineffective due to side effects and multi-drug resistance. Alkaloids, flavonoids, terpenoids, lignans, and saponins are examples of natural products with antileukemic properties that are also less toxic and effective against multi-drug resistance, making them an alternative and viable treatment option. NPs not only can combat CML cells' multi-drug resistance (MDR) as well as can separate them into the monocyte/erythroid lineage. In this paper, we will discuss the pathophysiology of chronic myeloid leukemia (CML) and the importance of various alkaloids in treating CML. In molecular docking of various antileukemic alkaloids with ABL-kinase, Curine shows maximum binding affinity using nilotinib as a control depicting its highly effective antileukemic property which can be used to formulate various other novel treatments for CML.